# An Evaluation of Weight Gain in Patients Treated with Dolutegravir vs. Other Core Agents (208943)

**First published:** 11/01/2019

**Last updated:** 02/07/2024





### Administrative details

EU PAS number	
EUPAS27523	
Study ID	
42173	
DARWIN EU® study	
No	
Study countries	
-	
United States	

#### **Study status**

**Finalised** 

Research institutions and networks

### Institutions

### ViiV Healthcare

First published: 01/02/2024

**Last updated:** 01/02/2024

Institution

## Contact details

### **Study institution contact**

GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor Pharma.CDR@gsk.com

Study contact

Pharma.CDR@gsk.com

### **Primary lead investigator**

GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor

Primary lead investigator

## Study timelines

Date when funding contract was signed

Planned: 14/12/2017

Actual: 14/12/2017

#### Study start date

Planned: 18/01/2019

Actual: 18/01/2019

#### Data analysis start date

Actual: 01/05/2019

#### Date of final study report

Planned: 30/08/2019

Actual: 07/10/2019

## Sources of funding

• Pharmaceutical company and other private sector

## More details on funding

ViiV Healthcare

## Study protocol

viiv-208943-protocol-redact.pdf (1.39 MB)

## Regulatory

### Was the study required by a regulatory body?

No

### Is the study required by a Risk Management Plan (RMP)?

Not applicable

## Methodological aspects

### Study typo

#### **Study topic:**

Disease /health condition

Human medicinal product

#### Study type:

Non-interventional study

### Scope of the study:

Other

### If 'other', further details on the scope of the study

Observational cohort analysis

#### **Data collection methods:**

Secondary use of data

### Main study objective:

To describe BMI categories, weight, lipid levels, and lipodystrophy among new users of DTG and other INSTIs at core agent initiation and at 6, 12, and 24 months after core agent initiation (stratified by ART- naïve and ART experienced) and to estimate the association between specific core agent initiation and changes in BMI at 6, 12, and 24 months after core agent initiation

## Study Design

### Non-interventional study design

Cohort

## Study drug and medical condition

### Study drug International non-proprietary name (INN) or common name

**DOLUTEGRAVIR** 

#### Medical condition to be studied

Human immunodeficiency virus transmission

## Population studied

#### Short description of the study population

The analysis population will be identified from the OPERA Observational Database according to the inclusion criteria defined below.

Primary population

- 1) A diagnosis of HIV-1, a positive HIV-1 Western Blot, or a positive HIV-1-specific ELISA; and a detectable HIV-1 viral load test
- 2) At least 18 years of age at the index date
- 3) Male or female patients
- 4) Prescribed DTG, RPV, RAL, BIC, EVG/c and DRV(/r/c) as part of a 3-drug regimen for the first time between 01AUG2013 and 31DEC2017
- 5) Not exposed to >1 core agent of interest concurrently
  Subjects with the following criteria will be excluded from the study sample:
- 1) HIV-negative
- 2) A diagnosis of HIV-2, a positive HIV-1/HIV-2 Multispot, a positive HIV-2-specific ELISA, a positive HIV-2 Western Blot or a detectable HIV-2 viral load test
- 3) Women who are considered pregnant at the index date
- 4) Transgender patients (potential for weight changes due to hormone use)

#### Secondary population

The study population for the secondary objectives will be a subset of the

primary study population meeting the following additional inclusion criteria:

- 1) Patients switching to DTG, RPV, RAL, BIC, EVG/c or DRV(/r/c) as part of a 3-drug regimen for the first time between 01AUG2013 and 31DEC2017 (excluding ARTnaïve patients)
- 2) Patients with a viral load <200 copies/mL at last viral load test prior to switch to core agent of interest

#### Age groups

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

### **Special population of interest**

Immunocompromised

### **Estimated number of subjects**

15000

## Study design details

#### **Data analysis plan**

Descriptive statistics will be used to summarize baseline demographic and clinical characteristics, as well as weight, lipid, and lipodystrophy outcomes at each time point (6,12, and 24 months). Pairwise comparisons will be made between DTG and other core agents. Adjusted linear regression models will be used to assess the association between core agent and mean changes in BMI at 6, 12, and 24 months. Baseline variables meeting the definition of a confounder will be included in the adjusted models, and will be selected a priori. The

analysis will be stratified by baseline BMI categories (underweight, normal weight, overweight, obese).

### **Documents**

#### Study results

viiv-208943-clinical-study-report-redact.pdf (5.71 MB)

## Data management

### **ENCePP Seal**

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

### Data sources

### **Data sources (types)**

Electronic healthcare records (EHR)

## Use of a Common Data Model (CDM)

### **CDM** mapping

No

## Data quality specifications

### **Check stability**

**Check conformance** 

Unknown

### **Check logical consistency**

Unknown

## Data characterisation

### **Data characterisation conducted**

No